- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01467258
Urinary Excretion of Acetylamantadine by Normal Healthy Volunteers
Amantadine appears to be a specific substrate for acetylation by spermidine/spermine N1-acetyltransferase (SSAT). SSAT activity in cancer cells is higher by several-fold compared to normal cells. Amantadine can be used to determine SSAT cellular activity, and may indicate the presence of cancer.
This study will provide additional information in conjunction with data from a previous study which include cancer patients and normal health age matched controls to determine whether urinary excretion of acetylamantadine is predictive for the presence of cancer, and if so whether excretion of this metabolite is associated with any particular site of the tumor. Based on the results of the first study additional data in normal healthy volunteers is required.
The data from both studies will be analyzed to account for subject gender, stage of disease at time of testing, concurrent diseases, alcohol and tobacco use and occupational characteristics. This is an important first step in validating a cancer detection method that can be implemented economically for screening of large numbers of people at sites remote from limited and expensive diagnostic instrumentation. Thus there is a possibility that this design can be prognosis biomarker as well as a positive/negative indicator.
Study Overview
Detailed Description
A group of 20 female and 20 male normal healthy volunteers ages 18 to 69 will be recruited from the community by use of a general advertisement placed initially as posters.
We will tell the volunteers that we are conducting this study in healthy volunteers to determine how amantadine is eliminated from the body. We will explain the pharmacology of amantadine and the potential side effects of a single dose before we obtain consent. Volunteers will be told of the potential for concurrent alcohol ingestion to result in the presence of acetylamantadine in urine. Volunteers will be required to abstain from alcohol consumption for at least one day prior to and including the time involved in the amantadine ingestion and urine collection. Any previous adverse reaction to amantadine will exclude a person from volunteering from this study. Subjects will be informed that side effects from this drug ingestion are highly unlikely because only a single dose will be administered. Any side effects if they occur will be related to the effect of amantadine on the brain. These effects may include insomnia, jitteriness, difficulty in concentrating and mental depression. However, these are the side effects associated with chronic ingestion of amantadine and are highly unlikely to occur with ingestion of a single dose. Once consent is obtained, the volunteers will ingest a therapeutic dose of amantadine (200 mg) in the morning, at least 2 hours before breakfast, and their complete urine will be collected over a period of 12 hours post dose. A previous clinical study in our laboratory with collections of urine for a total of 8 hours demonstrated that this collection time was sufficient to collect all metabolically produced acetylamantadine in the urine. The urine samples will also be analyzed for their content of creatinine as an indication of the completeness of the urine collection. The urines will then be labeled with a code and frozen at -20°C until analyzed. The urine will be analyzed for acetylamantidine by our established gas chromatography method. The technician analyzing the samples will not have access to any participant information other then the code on the label. Saliva specimens will also be collected at 2 hour intervals after amantadine ingestion. It should be noted that with the morning dose of amantadine collection of multiple saliva samples will be simplified and allow for the determination of the optimal time after dose for the urine analysis. Furthermore, this design will identify the window of opportunity to give the best signal to noise ratio for acetylamantidine production. Blood samples will be collected 1 hour prior to dosing and 2 hours post dose.
We will also collect the following data from each volunteer: their name, age, sex, body weight, height, any concurrent medication use, and a recent history of alcohol ingestion. These data will be used for correlation analyses to determine any relationship of urinary acetylamantidine to the particular cancer diagnosis, sex, and/or the history of alcohol consumption. All of these data will be coded by the principal investigator, and individually identifying information locked in a secure cabinet. Access to the data by other than the principal investigator and/or their attending physician will not be allowed.
Exclusion criteria are anyone with a history of previous adverse reaction to amantadine as well as pregnant or lactating females will be excluded from volunteering for this study.
Cross validation of the finding will occur by high performance liquid chromatography (HPLC) of these urine samples for the presence of polyamines and metabolites, including N1-acetylspermidine.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R2H 2A6
- St. Boniface General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Normal Healthy Volunteers (20 female and 20 male)
- Ages 18-69
Exclusion Criteria:
- Previous adverse reaction of amantadine
- Pregnant or lactating females
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Amantadine
Single dose
|
Single dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Amount of N-acetylamantadine excreted in a 12 hour urine sample collected after a signle oral dose of amatadine hydrochloride ingested 2 hours before breakfast
Time Frame: 12 hours after dosing
|
12 hours after dosing
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Bram Ramjiawan, Ph.D., St. Boniface Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Peripheral Nervous System Agents
- Antiviral Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Dopamine Agents
- Antiparkinson Agents
- Anti-Dyskinesia Agents
- Amantadine
Other Study ID Numbers
- B2011:073
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Metabolism
-
Wageningen UniversityUniversity Medical Center Groningen; Cereal Partners Worldwide; TNO; Nederlands... and other collaboratorsCompleted
-
Zhujiang HospitalZhongshan Bo Ai HospitalActive, not recruitingHealthy | Microbiome | MetabolismChina
-
University of TorontoNatural Sciences and Engineering Research Council, Canada; Mondelēz International... and other collaboratorsCompletedHealthy | Glucose MetabolismCanada
-
University of SurreyImperial College London; University of ReadingCompletedHealthy | Lipid Metabolism | LipidsUnited Kingdom
-
Helga EllingsgaardNot yet recruitingHealthy Volunteers Only | Energy MetabolismDenmark
-
University of British ColumbiaNot yet recruitingOne-carbon Metabolism in Healthy IndividualsCanada
-
Genzyme, a Sanofi CompanyCompletedHealthy Volunteers | Disorders of Sphingolipid MetabolismUnited Kingdom
-
Pyramid BiosciencesCompletedAbsorption, Metabolism and Excretion in Healthy VolunteersUnited States
-
Wake Forest University Health SciencesNational Center for Complementary and Integrative Health (NCCIH); Office of...CompletedGenetic Differences of Lipid Metabolism/Healthy SubjectsUnited States
-
Maastricht University Medical CenterTerminatedCerebral Blood Flow | Healthy Diet | Cognitive Performance | Glucose Metabolism | Healthy Lifestyle | Physical Exercise | Cerebrovascular CirculationNetherlands
Clinical Trials on Amantadine
-
Assiut UniversityRecruitingIntubation, IntratrachealEgypt
-
TC Erciyes UniversityUnknown
-
Xinhua Hospital, Shanghai Jiao Tong University...The Affiliated Hospital of Qingdao University; Shanghai University of Traditional... and other collaboratorsUnknownL-DOPA-Induced DyskinesiaChina
-
Adamas Pharmaceuticals, Inc.TerminatedParkinson's Disease | Levodopa Induced Dyskinesias (LID)France, Spain, Germany, Canada, United States
-
Dokuz Eylul UniversityUnknown
-
Sheba Medical CenterCompletedFatigue | Ataxia | Dystonia | Parkinsonism | ChoreaIsrael
-
Assiut UniversityCompletedSpinal CurvaturesEgypt
-
Wake Forest University Health SciencesWithdrawnTraumatic Brain InjuryUnited States
-
CancerCare ManitobaUniversity of Manitoba; Canadian Institutes of Health Research (CIHR); The Metabolomics... and other collaboratorsRecruiting
-
Methodist Rehabilitation CenterU.S. Department of EducationCompletedDelirium | Traumatic Brain Injury | Posttraumatic Confusional StateUnited States